Clascoterone: First Approval

    October 2020 in “ Drugs ”
    Sohita Dhillon
    Studysummary This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris American Journal of Clinical Dermatology · 2019
    2. Cortexolone 17α-Propionate (Clascoterone) Is an Androgen Receptor Antagonist in Dermal Papilla Cells In Vitro PubMed · 2019
    3. Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist Drug Research · 2011

    Related research 1

    1. C-MYC-Induced Sebaceous Gland Differentiation Is Controlled by an Androgen Receptor/p53 Axis Cell reports · 2013